Keytruda

Bristol-Myers Squibb Co (NYSE: BMY) shares are sliding Thursday despite the company reporting forecast-beating Q4 results. The negative sentiment could be traced back to a regulatory update the company issued for its cancer drug combo that is being evaluated for lung cancer. What Happened Bristol-...

After a strong 2017, biotech stocks are on track to end the year in the red despite a record 59 new molecular entity approvals, some noteworthy M&A deals and several breakthrough developments in drug discovery and research. Will the new year mark a reversal in fortunes for these firms? Here...

The year is drawing to the close, and biotech stocks have had a fairly good run despite the market-wide downturn in October and Novmeber. New molecular moiety (NME) approvals thus far this year totaled 52, already beating the previous year's number of 46. NMEs are active moieties that...

Large-cap pharma stocks have had a decent 2018, with strong earnings momentum primarily responsible for the optimism in the space. Tax cuts enabled companies to augment cash reserves, giving them flexibility to pursue inorganic growth to enrich product pipelines. Here's how large...

October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500's 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA...

The month of May saw several drugs passing the FDA muster, with new molecular entity approvals alone totaling five. NMEs are those innovative new products containing active moieties that haven't been approved by the agency previously, either as a single ingredient drug, or as part of a...

The U.S. Food and Drug Administration issued an alert on issues discovered in ongoing studies of Merck & Co., Inc. (NYSE: MRK)’s Keytruda Roche’s Tecentriq, according to a headline from Bloomberg. Regulators reportedly found that some patients had decreased survival. Why It’...

Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial. What Happened Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...

The biotech space wasn't immune to the broader market sell-off in March, although the degree of negativity was less pronounced among defensive biotech stocks. Rising demand for drugs, as the population ages, the prospects of the FDA expediting approval process as the Trump administration...

Merck & Co., Inc. (NYSE: MRK) announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped patients live longer and played a role in stopping the disease from advancing...

The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-...

Analysts at Barclays no longer hold a bullish view on Merck & Co., Inc. (NYSE: MRK) due to a now diminished potential for its biggest value driver, Keytruda. The firm's Geoff Meacham downgraded Merck's stock rating from Overweight to Equal Weight with a price target slashed from $72 to $62....

Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from $65 to $72. The new bullish stance stems from increased conviction of Merck's...

Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK) both release their second quarter earnings reports this week. According to BMO Capital, investors should be buying Merck and selling Bristol-Myers ahead of earnings. Despite Merck being on the verge of...

The hot biotech space is set to witness a month of brimming activity in June, as several prospective treatment candidates are up on the altar to receive the blessings of the FDA. Two new molecular entities were approved in May, taking the tally for this year to 20. How The Sector Has Fared Thus...